Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report) and keeping the price target at ...

Nearly 2,000 people have taken part in a groundbreaking trial that aims to help doctors identify more people at risk of ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

Large-capitalization blue-chip dividend stocks are a favorite among investors for a good reason. They provide a steady stream ...

Explore the recent performance of the SCHD ETF's performance in 2024 and what to expect in the next few months and why it may ...

By contrast, the most common Cobenfy side effects in clinical trials were somewhat mild by comparison: nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, increased ...

Recognizing the increased use of artificial intelligence in the development of new therapies, the U.S. FDA on Monday released ...